Class 3 Medicines Recall: Norgine Limited, MOVICOL Ease Citrus Powder for oral solution 13.7 g, EL(26)A/08
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 17 Feb 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Norgine Limited is recalling one batch of product as a precautionary measure due to some units containing low amounts of active ingredients.
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information
A%2F41/og.png)
Professional
Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F42/og.png)
Professional
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F47/og.png)
Professional
Class 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/47
Aspire Pharma Ltd is recalling specific batches of Tropicamide 1% Eye Drops, solution in single dose containers 0.5ml x 20, due to them being labelled with the incorrect expiry date. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines,.
by Medicines and Healthcare products Regulatory Agency (MHRA)
%2C%20EL(26)A%2F43/og.png)
Professional
Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43
Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F46/og.png)
Professional
Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46
Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines.
by Medicines and Healthcare products Regulatory Agency (MHRA)
A%2F48/og.png)
Professional
Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48
Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton... Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
17 Feb 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- BD BodyComm™ version 3.3 software used for BodyGuard infusion pumps, BodyGuard-T and T34 syringe drivers: Important steps to manage transition to Windows 11 (DSI/2025/006)
- Class 2 Medicines Recall: Regent Medical Limited / Mölnlycke Health Care, Hibiwash 500ml, EL(26)A/15
- Class 2 Medicines Recall: Rokshaw Limited Trading as Curaleaf Laboratories, Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml), EL(26)A/13
- Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
- Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
- Class 4 Medicines Defect Notification: Blumont Pharma Limited, Ocumont Eye Ointment 1% w/w, EL(26)A/03
- Class 4 Medicines Defect Notification: Special Concept Development UK Limited, Baclofen 10mg Tablets, EL(25)A/51
- Field Safety Notices for 05-09 January 2026
- Field Safety Notices: 02-06 February 2026
- Field Safety Notices: 6 October to 10 October 2025
- Field Safety Notices: 6 to 10 April 2026
- Field Safety Notices: 8 - 12 December 2025
- Field Safety Notices: 11 to 15 August 2025
- Field Safety Notices: 15 - 19 December 2025
- Field Safety Notices: 17 to 21 November 2025
- Field Safety Notices: 20 to 24 October 2025
- Field Safety Notices: 24 to 28 November 2025
- MHRA Safety Roundup: September 2025
- Profemur Cobalt Chrome Modular Neck Hip Replacements: Higher than anticipated risk of revision surgery, metal-wear effects and component fracture (DSI/2025/005)
- Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error


